PDCD1 and neoplasm: For instance, the modified IL-10 pegilodecakin enhanced response rates and durability of benefits, especially combined with PD-1 blockade in NSCLC,556 renal cell carcinoma (RCC),557 and melanoma558 patients, even in settings with unfavorable immunological features, such as no PD-L1 expression, low tumor mutational burden, presence of liver metastasis, and progression on prior checkpoint blockade.